The pathogenesis of mesothelioma is driven by a dysregulated translatome
- PMID: 34389715
- PMCID: PMC8363647
- DOI: 10.1038/s41467-021-25173-7
The pathogenesis of mesothelioma is driven by a dysregulated translatome
Abstract
Malignant mesothelioma (MpM) is an aggressive, invariably fatal tumour that is causally linked with asbestos exposure. The disease primarily results from loss of tumour suppressor gene function and there are no 'druggable' driver oncogenes associated with MpM. To identify opportunities for management of this disease we have carried out polysome profiling to define the MpM translatome. We show that in MpM there is a selective increase in the translation of mRNAs encoding proteins required for ribosome assembly and mitochondrial biogenesis. This results in an enhanced rate of mRNA translation, abnormal mitochondrial morphology and oxygen consumption, and a reprogramming of metabolic outputs. These alterations delimit the cellular capacity for protein biosynthesis, accelerate growth and drive disease progression. Importantly, we show that inhibition of mRNA translation, particularly through combined pharmacological targeting of mTORC1 and 2, reverses these changes and inhibits malignant cell growth in vitro and in ex-vivo tumour tissue from patients with end-stage disease. Critically, we show that these pharmacological interventions prolong survival in animal models of asbestos-induced mesothelioma, providing the basis for a targeted, viable therapeutic option for patients with this incurable disease.
© 2021. The Author(s).
Conflict of interest statement
The authors declare no competing interests with the exception of the Murphy lab, which currently receives funding from Puma Biotechnology and the Merck Group for work unrelated to this manuscript.
Figures







Similar articles
-
Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.EMBO J. 2020 Nov 2;39(21):e105111. doi: 10.15252/embj.2020105111. Epub 2020 Sep 18. EMBO J. 2020. PMID: 32945574 Free PMC article.
-
4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.Invest New Drugs. 2018 Apr;36(2):217-229. doi: 10.1007/s10637-017-0535-z. Epub 2017 Nov 8. Invest New Drugs. 2018. PMID: 29116477
-
Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma.Biomed Pharmacother. 2021 Jan;133:110906. doi: 10.1016/j.biopha.2020.110906. Epub 2020 Nov 13. Biomed Pharmacother. 2021. PMID: 33190037
-
Use of preclinical models for malignant pleural mesothelioma.Thorax. 2021 Nov;76(11):1154-1162. doi: 10.1136/thoraxjnl-2020-216602. Epub 2021 Mar 10. Thorax. 2021. PMID: 33692175 Free PMC article. Review.
-
Genomics and Functional Genomics of Malignant Pleural Mesothelioma.Int J Mol Sci. 2020 Sep 1;21(17):6342. doi: 10.3390/ijms21176342. Int J Mol Sci. 2020. PMID: 32882916 Free PMC article. Review.
Cited by
-
Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells.Cell Death Dis. 2023 Nov 8;14(11):725. doi: 10.1038/s41419-023-06240-x. Cell Death Dis. 2023. PMID: 37938546 Free PMC article.
-
Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma.Cells. 2022 Sep 19;11(18):2924. doi: 10.3390/cells11182924. Cells. 2022. PMID: 36139498 Free PMC article.
-
Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.Target Oncol. 2022 Jul;17(4):407-431. doi: 10.1007/s11523-022-00900-2. Epub 2022 Jul 30. Target Oncol. 2022. PMID: 35906513 Free PMC article. Review.
-
Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma.Front Toxicol. 2023 Jun 27;5:1200650. doi: 10.3389/ftox.2023.1200650. eCollection 2023. Front Toxicol. 2023. PMID: 37441092 Free PMC article.
-
Methodology for generating chorioallantoic membrane patient-derived xenograft (CAM-PDX) models of pleural mesothelioma and performing preclinical imaging for the translation of cancer studies and drug screening.F1000Res. 2025 Aug 14;14:481. doi: 10.12688/f1000research.163596.2. eCollection 2025. F1000Res. 2025. PMID: 40568242 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- 29252/CRUK_/Cancer Research UK/United Kingdom
- MR/K00252X/1/MRC_/Medical Research Council/United Kingdom
- MC_UP_1203/1/MRC_/Medical Research Council/United Kingdom
- DH_/Department of Health/United Kingdom
- 28879/CRUK_/Cancer Research UK/United Kingdom
- MC_UU_00025/7/MRC_/Medical Research Council/United Kingdom
- 5TR019/MRC_/Medical Research Council/United Kingdom
- PCL/18/06/CSO_/Chief Scientist Office/United Kingdom
- A17196/CRUK_/Cancer Research UK/United Kingdom
- MCA/600/MRC_/Medical Research Council/United Kingdom
- MC_EX_G0902052/MRC_/Medical Research Council/United Kingdom
- 29372/CRUK_/Cancer Research UK/United Kingdom
- 21139/CRUK_/Cancer Research UK/United Kingdom
- A29252/CRUK_/Cancer Research UK/United Kingdom
- MC_UP_A600_1024/MRC_/Medical Research Council/United Kingdom
- MC_UU_00025/4/MRC_/Medical Research Council/United Kingdom
- 5TR00/MRC_/Medical Research Council/United Kingdom
- MC_UU_00025/6/MRC_/Medical Research Council/United Kingdom
- A21139/CRUK_/Cancer Research UK/United Kingdom
- 24388/CRUK_/Cancer Research UK/United Kingdom
- 30062/CRUK_/Cancer Research UK/United Kingdom
- MC_UP_A600_1023/MRC_/Medical Research Council/United Kingdom
- MC_UU_00025/5/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Molecular Biology Databases